Clean Yield Group lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 360,091 shares of the company's stock after selling 46,137 shares during the period. Takeda Pharmaceutical makes up about 1.5% of Clean Yield Group's portfolio, making the stock its 17th biggest position. Clean Yield Group's holdings in Takeda Pharmaceutical were worth $4,768,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the stock. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical during the 4th quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical during the third quarter valued at $40,000. EverSource Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after purchasing an additional 859 shares during the last quarter. BNP Paribas Financial Markets grew its position in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after purchasing an additional 2,596 shares during the period. Finally, Smithfield Trust Co raised its stake in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after buying an additional 1,490 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
Shares of TAK traded up $0.05 during mid-day trading on Monday, reaching $13.00. The company had a trading volume of 1,828,047 shares, compared to its average volume of 2,319,564. The stock has a market capitalization of $41.36 billion, a P/E ratio of 22.41, a PEG ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The stock has a 50 day moving average of $13.44 and a two-hundred day moving average of $13.90. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
